Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01042977 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety in Patients With Type 2 Diabetes Mellitus and Cardiovascular Disease
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 964
- Enrollment target
NCT01042977 is a Phase 3 study that has completed, run by AstraZeneca. The registered enrollment target is 964 participants.
The verdict
NCT01042977, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 964 participants
- Enrollment target
Study Summary
This study is carried out to assess whether dapagliflozin improves glycemic control, decreases fasting plasma glucose levels, body weight and blood pressure when added to patient's existing medications and how it compares with their usual treatment without added dapagliflozin. Safety data will be collected and analysed to confirm that treatment with dapagliflozin is safe and well tolerated in patients who have diabetes and cardiovascular disease
Interventions
- DRUG Placebo
- DRUG Dapagliflozin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 964 participants |
| Start Date | 2010-03 |
| Est. Completion | 2012-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01042977
The ClinicalTrials.gov registry entry for NCT01042977 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 964 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01042977 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01042977 about?
NCT01042977 is a clinical study titled "Efficacy and Safety in Patients With Type 2 Diabetes Mellitus and Cardiovascular Disease". This study is carried out to assess whether dapagliflozin improves glycemic control, decreases fasting plasma glucose levels, body weight and blood pressure when added to patient's existing medications and how it compares with their usual treatment without added dapagliflozin. Safety data will be co...
What is the current status of trial NCT01042977?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 964 participants. The study started on 2010-03. Estimated completion is 2012-12.
What interventions are being tested in trial NCT01042977?
The interventions under investigation include: Placebo (DRUG), Dapagliflozin (DRUG).
Who is sponsoring clinical trial NCT01042977?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.